Product
AI AGENTS
AI APPLICATIONS
OTHERS
Solutions
INDUSTRIES
Pricing
Resources
EXPLORE
ENGAGE
SUPPORT & SERVICES
About
PatSnap Eureka Platform
Agents for IP
Agents for Engineering
Agents for Life Sciences
Agents for Materials
Analytics
IP IntelligenceSynapse
Biopharma IntelligenceBio
Biosequence Search and AnalysisChemical
Chemical Structure Search and AnalysisEureka AI Inside
Professional Services
Customer Stories
Blog
Global Innovation Report
Glossary
Webinars & Training
Frontier
User Community
Trust and Security
PatentBench
LLM
Help center
Careers
Access to over 2,000,000,000 structured data points around patents, science, litigation, and tech sectors
Innovate 75% faster at 25% less cost
Cloud or on-prem for maximum privacy and control
Trusted by more than 18,000 innovators worldwide
To use , click the vertification button in the email we sent to [email protected].
This helps keep your account secure.
You should receive it shortly. Don’t forget to check your spam folder.
Thoughtfully curated series offering valuable insights for innovation professionals
Article | Report How RORγt inverse agonists (VTP-43742, ABBV-157) differ mechanistically from IL-23p19 antibodies in Th17 suppression — clinical tolerability, tissue pharmacodynamics, and patent evidence.
Article | Report How do oral small molecule IL-17A inhibitors compare to Bimekizumab? Explore the mechanistic rationale, patent landscape, and oral bioavailability solutions.
Article | Report Explore Applied Materials' semiconductor deposition, etch, and materials engineering technology roadmap from 2010 to 2026—key innovations, process trends, and future outlook.
Article | Report Silicon photonics vs. InP vs. thin-film LiNbO₃: a 2026 PIC technology landscape covering data center demand, performance benchmarks, and market growth.
Article | Report How satralizumab, sarilumab, and siltuximab differ in IL-6 pathway blockade, CNS penetrance, and patent-disclosed antibody engineering for half-life extension.
Article | Report MBCFET vs nanosheet vs forksheet: compare GAA transistor architectures, process integration challenges, and the 2026 competitive landscape from Samsung to TSMC.
Article | Report Telitacicept vs. Belimumab in IgA nephropathy and SLE: mechanistic rationale for dual APRIL/BAFF blockade and clinical evidence on IgA levels, proteinuria, and B-cell dynamics.
Article | Report How allosteric TYK2 pseudokinase inhibition achieves IL-12/IL-23/IFN-α selectivity while avoiding JAK1/2/3 hematopoietic and thromboembolic risks — clinical evidence in psoriasis and SLE.
Article | Report How PKMYT1 co-inhibition in Lunresertib overcomes CDK1 compensation at the G2/M checkpoint — and what patent-disclosed structural optimizations reveal about selectivity over Adavosertib.
Article | Report How Texas Instruments evolved its analog, embedded processing, and precision signal chain portfolio from 2010 to 2026—patents, process strategy, and key milestones.
Article | Report Ammonia cracking catalysts, synthesis routes, and shipping infrastructure vs. liquid H₂: the 2026 technology landscape for ammonia as a hydrogen carrier.
Article | Report How SOS1::KRAS inhibitors (BI-1701963, RMC-0708) and SHP2 allosteric inhibitors (TNO155, RMC-4630) tackle adaptive RTK reactivation in KRAS-mutant NSCLC — mechanism and trial evidence.
Article | Report Molten salt, phase change materials, and thermochemical systems for industrial decarbonization: patent trends, TRL ratings, LCOH data, and 2030 deployment roadmap.
Article | Report How Infineon built a dominant SiC power semiconductor position: 2,265 patents, €5bn manufacturing investment, and three generations of CoolSiC™ MOSFET technology.
Article | Report How PRMT5 inhibitors exploit synthetic lethality via the methionine salvage pathway versus EZH2 inhibition — pipeline evidence, biomarker selection, and clinical differentiation.